

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

1 Best Practices on Use of Nitrous Oxide for Pediatric Dental Patients

2

3 Review Council

4 Council on Clinical Affairs

5 Latest Revision

6 ~~2013~~ 2018

7

8 Purpose

9 The American Academy of Pediatric Dentistry (AAPD) recognizes nitrous oxide/oxygen inhalation as a
10 safe and effective technique to reduce anxiety, produce analgesia, and enhance effective communication
11 between a patient and health care provider. The need to diagnose and treat, as well as the safety of the
12 patient and practitioner, should be considered before using nitrous oxide. By producing this guideline, the
13 AAPD intends to assist the dental profession in developing appropriate practices in the use of nitrous
14 oxide/oxygen analgesia/anxiolysis for pediatric patients.

15

16 Methods

17 This guideline was originally developed by the Council on Clinical Affairs ~~Committee~~ and adopted in
18 2005. This document is a revision of the previous version, last revised in 2013~~09~~. The revision is based on
19 a review of the current dental and medical literature related to nitrous oxide use. An electronic search was
20 conducted using PubMed® with the terms: nitrous oxide, analgesia, anxiolysis, behavior management,
21 diffusion hypoxia, scavenging, occupational exposure, and dental treatment; fields: all; limits: within the
22 last 10 years, humans, English, and clinical trials. Forty articles met these criteria, and papers were added
23 to the references from the previous document. Additionally, the American Dental Association Guideline
24 for the use of sedation and general anesthesia by dentists and the American Dental Association Oral
25 Health Topics – Nitrous oxide dental best practices for nitrous oxide-oxygen use were reviewed. When
26 data did not appear sufficient or were inconclusive, recommendations were based upon expert and/or
27 consensus opinion by experienced researchers and clinicians.

28

29 Background

30 Dentists have expertise in providing anxiety and pain control for their patients. While anxiety and pain
31 can be modified by psychological techniques, in many instances pharmacological approaches are
32 required¹. Analgesia/anxiolysis is defined as diminution or elimination of pain and anxiety in a conscious

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

33 patient². The patient responds normally to verbal commands. All vital signs are stable, there is no
34 significant risk of losing protective reflexes, and the patient is able to return to pre-procedure mobility. In
35 children, analgesia/anoxiolysis may expedite the delivery of procedures that are not particularly
36 uncomfortable, but require that the patient not move². It also may allow the patient to tolerate unpleasant
37 procedures by reducing or relieving anxiety, discomfort, or pain. The use of nitrous oxide increases
38 reaction time, reduces pressure-induced pain, but does not affect pulpal sensitivity, as shown in a double-
39 blind, crossover study³. The outcome of pharmacological approaches is variable and depends upon each
40 patient's response to various drugs. The clinical effect of nitrous oxide/oxygen inhalation, however, is
41 more predictable among the majority of the population.

42

43 Nitrous oxide is a colorless and virtually odorless gas with a faint, sweet smell. It is an effective
44 analgesic/anoxiolytic agent causing central nervous system (CNS) depression and euphoria with little
45 effect on the respiratory system^{4,5}. Nitrous oxide has multiple mechanisms of action. The analgesic effect
46 of nitrous oxide appears to be initiated by neuronal release of endogenous opioid peptides with
47 subsequent activation of opioid receptors and descending Gamma-aminobutyric acid type A (GABAA)
48 receptors and noradrenergic pathways that modulate nociceptive processing at the spinal level. The
49 anoxiolytic effect involves activation of the GABAA receptor either directly or indirectly through the
50 benzodiazepine binding site^{6,7}. Nitrous oxide has rapid uptake, being absorbed quickly from the alveoli
51 and held in a simple solution in the serum. It is relatively insoluble, passing down a gradient into other
52 tissues and cells in the body, such as the CNS. It is excreted quickly from the lungs. ~~As nitrous oxide is~~
53 ~~34 times more soluble than nitrogen in blood, diffusion hypoxia may occur. Studies (Patel et al 1994,~~
54 ~~Patel, Norden and Hannallah 1988, Kinouci et al 1992) have shown that children desaturate more rapidly~~
55 ~~than adolescents, and administering 100 percent oxygen to the patient once the nitrous oxide in a closed-~~
56 ~~system has been terminated is important (Patel et al 1994).~~ Nitrous oxide causes minor depression in
57 cardiac output while peripheral resistance is slightly increased, thereby maintaining the blood pressure⁴.
58 This is of particular advantage in treating patients with cerebrovascular system disorders.

59

60 Nitrous oxide is absorbed rapidly, allowing for both rapid onset and recovery (two to three minutes). It
61 causes minimal impairment of any reflexes, thus protecting the cough reflex⁴. It exhibits a superior safety
62 profile with no recorded fatalities or cases of serious morbidity when used within recommended
63 concentrations⁸⁻¹¹ (Nathan 1989). ~~Studies have reported negative outcomes associated with use of nitrous~~
64 ~~oxide greater than 50 percent and as an anesthetic during major surgery (Schmitt and Baum 2008, Zeir~~
65 ~~and Doescher 2010). Although rare, silent regurgitation and subsequent aspiration need to be considered~~

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

66 with nitrous oxide/oxygen sedation. The concern lies in whether pharyngeal-laryngeal reflexes remain
67 intact. This problem can be avoided by not allowing the patient to go into an unconscious state (Hogue,
68 Ternisky and Iranour 1971). Side effects such as nausea and vomiting are more likely to be observed
69 when titration is not employed (Malamed and Clark 2003). As nitrous oxide is 34 times more soluble
70 than nitrogen in blood, diffusion hypoxia may occur. This can be avoided by administering 100 percent
71 oxygen for five minutes once the nitrous oxide flow is terminated.

72

73 The decision to use nitrous oxide/oxygen analgesia/anoxiolysis must take into consideration alternative
74 behavioral guidance modalities, the patient's dental needs, the effect on the quality of dental care, the
75 patient's emotional development, and the patient's physical considerations. Nitrous oxide generally is
76 acceptable to children and can be titrated easily. Most children are enthusiastic about the administration of
77 nitrous oxide/oxygen; many children report feeling a tingling or warm sensation. Objectively, children
78 may appear with their hands open, legs limp, and with a trancelike expression¹². ~~dreaming or being on a~~
79 ~~“space ride”~~ (Hogue, Ternisky and Iranour 1971). For some patients, however, the feeling of “losing
80 control” may be troubling and children with claustrophobiae patients may find the nasal hood confining
81 and unpleasant¹³.

82

83 Nitrous oxide has been associated with bioenvironmental concerns because of its contribution to the
84 greenhouse effect¹⁴. Nitrous oxide is emitted naturally by bacteria in soils and oceans; it is produced by
85 humans through the burning of fossil fuels and forests and the agricultural practices of soil cultivation and
86 nitrogen fertilization. Altogether, nitrous oxide contributes about five percent to the greenhouse effect^{15,16}.
87 Only a small fraction of this five percent (0.35 to two percent), however, is actually the result of
88 combined medical and dental applications of nitrous oxide gas¹⁶.

89

90 The objectives of nitrous oxide/oxygen inhalation include:

- 91 1. Reduce or eliminate anxiety.
- 92 2. Reduce untoward movement and reaction to dental treatment.
- 93 3. Enhance communication and patient cooperation.
- 94 4. Raise the pain reaction threshold.
- 95 5. Increase tolerance for longer appointments.
- 96 6. Aid in treatment of the mentally/physically disabled or medically compromised patient.
- 97 7. Reduce gagging.
- 98 8. Potentiate the effect of sedatives.

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

99

100 Disadvantages of nitrous oxide/oxygen inhalation may include⁴:

- 101 1. Lack of potency.
- 102 2. Dependant largely on psychological reassurance.
- 103 3. Interference of the nasal hood with injection to anterior maxillary region.
- 104 4. Patient must be able to breathe through the nose.
- 105 5. Nitrous oxide pollution and potential occupational exposure health hazards.

106

107 Recommendations

108 Indications for use of nitrous oxide/oxygen analgesia/anxiolysis include:

- 109 1. A fearful, anxious, or obstreperous patient.
- 110 2. Certain patients with special health care needs.
- 111 3. A patient whose gag reflex interferes with dental care.
- 112 4. A patient for whom profound local anesthesia cannot be obtained.
- 113 5. A cooperative child undergoing a lengthy dental procedure.

114

115 Review of the patient's medical history should be performed prior to the decision to use nitrous
116 oxide/oxygen analgesia/anxiolysis. This assessment should include:

- 117 1. Allergies and previous allergic or adverse drug reactions.
- 118 2. Current medications including dose, time, route, and site of administration.
- 119 3. Diseases, disorders, or physical abnormalities and pregnancy status.
- 120 4. Previous hospitalization to include the date and purpose.
- 121 5. Recent illnesses (e.g., cold or congestion) that may compromise the airway.

122

123 Contraindications for use of nitrous oxide/oxygen inhalation may include:

- 124 1. Some chronic obstructive pulmonary diseases¹⁷.
- 125 2. Current upper respiratory tract infection¹⁸.
- 126 3. Recent middle ear disturbance/ surgery¹⁸.
- 127 ~~4.2~~ Severe emotional disturbances or drug-related dependencies¹⁸.
- 128 ~~5.3~~ First trimester of pregnancy¹⁹.
- 129 ~~6.4~~ Treatment with bleomycin sulfate²⁰.
- 130 ~~7.5~~ Methylene tetrahydrofolate reductase deficiency²¹.
- 131 ~~8.6~~ Cobalamin (Vit B12) deficiency⁷.

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

132
133 Whenever possible, appropriate medical specialists should be consulted before administering
134 analgesic/anxiolytic agents to patients with significant underlying medical conditions (e.g., severe
135 obstructive pulmonary disease, congestive heart failure, sickle cell disease²², acute otitis media, recent
136 tympanic membrane graft²³, acute severe head injury²⁴. In addition, consultation with the prenatal medical
137 provider should precede use of nitrous oxide/oxygen analgesia/ anxiolysis during pregnancy²⁵.

138
139 **Technique of nitrous oxide/oxygen administration**
140 Nitrous oxide/oxygen must be administered only by appropriately licensed individuals, or under the direct
141 supervision thereof, according to state law. The practitioner responsible for the treatment of the patient
142 and/or the administration of analgesic/anxiolytic agents must be trained in the use of such agents and
143 techniques and appropriate emergency response.

144
145 Selection of an appropriately sized nasal hood should be made. A flow rate of five to six L/min generally
146 is acceptable to most patients. The flow rate can be adjusted after observation of the reservoir bag. The
147 bag should pulsate gently with each breath and should not be either over- or underinflated. Introduction of
148 100 percent oxygen for one to two minutes followed by titration of nitrous oxide in 10 percent intervals is
149 recommended. During nitrous oxide/oxygen analgesia/anxiolysis, the concentration of nitrous oxide
150 should not routinely exceed 50 percent. Studies have demonstrated that gas concentrations dispensed by
151 the flow meter vary significantly from the end-expired alveolar gas concentrations; it is the latter that is
152 responsible for the clinical effects^{26,27}. To achieve sedation, the scavenging vacuum should not be so
153 strong as to prevent adequate ventilation of the lungs with nitrous oxide²⁸. A review of records of
154 patients undergoing nitrous oxide-oxygen inhalation sedation demonstrated that the typical patient
155 requires from 30 to 40 percent nitrous oxide to achieve ideal sedation (Malamed and Clark 2003).
156 Clinicians should keep patients' talking and mouth breathing to a minimum to prevent expired nitrous
157 oxide from contaminating the operator²⁹. Nitrous oxide concentration may be decreased during easier
158 procedures (e.g., restorations) and increased during more stimulating ones (e.g., extraction, injection of
159 local anesthetic). One study found that there was no benefit to continuous administration of nitrous oxide
160 after profound anesthesia had been achieved³⁰. Side effects such as nausea and vomiting are more likely
161 to be observed when titration is not employed (Malamed and Clark 2003). During treatment, it is
162 important to continue the visual monitoring of the patient's respiratory rate and level of consciousness.
163 The effects of nitrous oxide largely are dependent on psychological reassurance. Therefore, it is important
164 to continue traditional behavior guidance techniques during treatment. Once the nitrous oxide flow is

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

165 terminated, 100 percent oxygen should be administered until the patient has returned to pre-treatment
166 status³¹. ~~should be delivered for five minutes.~~ The patient must return to pretreatment responsiveness
167 before discharge.

168

169 **Monitoring**

170 The response of patients to commands during procedures performed with analgesia/anoxiolysis serves as a
171 guide to their level of consciousness. Clinical observation of the patient must be performed during any
172 dental procedure. During nitrous oxide/oxygen analgesia/anoxiolysis, continual clinical observation of the
173 patient's responsiveness, color, and respiratory rate and rhythm must be performed. Spoken responses
174 provide an indication that the patient is breathing². If any other pharmacologic agent is used in addition to
175 nitrous oxide/oxygen and a local anesthetic, monitoring guidelines for the appropriate level of sedation
176 must be followed³².

177

178 **Adverse effects of nitrous oxide/oxygen inhalation**

179 Nitrous oxide/oxygen analgesia/anoxiolysis has an excellent safety record. When administered by trained
180 personnel on carefully selected patients with appropriate equipment and technique, nitrous oxide is a safe
181 and effective agent for providing pharmacological guidance of behavior in children. Acute and chronic
182 adverse effects of nitrous oxide on the patient are rare³³. Nausea and vomiting are the most common
183 adverse effects, occurring in 0.5 – 1.2 percent of patients^{34,35}. A higher incidence is noted with longer
184 administration of nitrous oxide/oxygen, fluctuations in nitrous oxide levels, ~~and lack of titration,~~
185 increased concentrations of nitrous oxide, and a heavy meal prior to administration of nitrous oxide^{4,28,29} .
186 Fasting is not required for patients undergoing nitrous oxide analgesia/anoxiolysis. The practitioner,
187 however, may recommend that only a light meal be consumed in the two hours prior to the administration
188 of nitrous oxide³⁶. Studies have reported negative outcomes associated with use of nitrous oxide greater
189 than 50 percent and as an anesthetic during major surgery^{37,38}. Although rare, silent regurgitation and
190 subsequent aspiration need to be considered with nitrous oxide/oxygen sedation. The concern lies in
191 whether pharyngeal-laryngeal reflexes remain intact. This problem can be avoided by not allowing the
192 patient to go into an unconscious state³⁹.

193

194 As nitrous oxide is 34 times more soluble than nitrogen in blood, diffusion hypoxia may occur. Diffusion
195 hypoxia can occur as a result of rapid release of nitrous oxide from the blood stream into the alveoli,
196 thereby diluting the concentration of oxygen. This may lead to headache, ~~and~~ disorientation, and nausea
197 and can be avoided by administering 100 percent oxygen once the nitrous oxide flow is terminated⁴.

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

198 Diffusion hypoxia can occur as a result of rapid release of nitrous oxide from the blood stream into the
199 alveoli, thereby diluting the concentration of oxygen. This may lead to headache, and disorientation, and
200 nausea and can be avoided by administering 100 percent oxygen after nitrous oxide has been discontinued
201 (Paterson and Tahmassebi 2003). While the standard recommendation is to administer 100% oxygen at
202 the end of the procedure, several studies have questioned the necessity for this step in nitrous oxide
203 protocols in healthy patients^{18,40-42}.

204

205 **Documentation**

206 Informed consent must be obtained from the parent and documented in the patient's record prior to
207 administration of nitrous oxide/oxygen. The practitioner should provide instructions to the parent
208 regarding pretreatment dietary precautions, if indicated. In addition, the patient's record should include
209 indication for use of nitrous oxide/oxygen inhalation, nitrous oxide dosage (i.e., percent nitrous
210 oxide/oxygen and/or flow rate), duration of the procedure, and post treatment oxygenation procedure.

211

212 **Facilities/personnel/equipment**

213 All newly installed facilities for delivering nitrous oxide/oxygen must be checked for proper gas delivery
214 and fail-safe function prior to use. Inhalation equipment must have the capacity for delivering 100
215 percent, and never less than 30 percent, oxygen concentration at a flow rate appropriate to the child's size.
216 Additionally, inhalation equipment must have a fail-safe system that is checked and calibrated regularly
217 according to the practitioner's state laws and regulations³⁸. The system components, including the
218 reservoir bag, should be inspected routinely for cracks, wear, and tears. If detected, repairs should be
219 made immediately. Pressure connections should be tested for leaks when delivery system is turned on and
220 each time a tank is changed. ~~Compressed gas tanks must be kept in a locked room.~~ Consult state and
221 federal guidelines regarding storage of compressed gas tanks. Additional locks at the tanks, or mixer/
222 delivery level are available from many manufacturers to deter individuals from accessing nitrous oxide
223 inappropriately⁴³. If nitrous oxide/oxygen delivery equipment capable of delivering more than 70 percent
224 nitrous oxide and less than 30 percent oxygen is used, an inline oxygen analyzer must be used. The
225 equipment must have an appropriate scavenging system to minimize room air contamination and
226 occupational risk. The scavenging system should vent outside⁴⁴. Additionally, it has been shown that the
227 double-mask system is more effective than the single-mask system in the removal of waste nitrous
228 oxide^{46,47}.

229

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

230 The practitioner who utilizes nitrous oxide/oxygen analgesia/anxiolysis for a pediatric dental patient shall
231 possess appropriate training and skills and have available the proper facilities, personnel, and equipment
232 to manage any reasonably foreseeable emergency. The practitioner is responsible for managing the
233 potential complications associated with the intended level of sedation and the next deeper level.
234 Therefore, because moderate sedation may occur, practitioners should have the appropriate training and
235 emergency equipment to manage this³¹. Training and certification in basic life support are required for all
236 clinical personnel. These individuals should participate in periodic review of the office's emergency
237 protocol, the emergency drug cart, and simulated exercises to assure proper emergency management
238 response.

239
240 An emergency cart (kit) must be readily accessible. Emergency equipment must be able to accommodate
241 children of all ages and sizes. It should include equipment to resuscitate a non-breathing, unconscious
242 patient and provide continuous support until trained emergency personnel arrive. A positive-pressure
243 oxygen delivery system capable of administering greater than 90 percent oxygen at a 10 L/min flow for at
244 least 60 minutes (650 L, "E" cylinder) must be available. When a self-inflating bag valve mask device is
245 used for delivering positive pressure oxygen, a 15 L/min flow is recommended. There should be
246 documentation that all emergency equipment and drugs are checked and maintained on a regularly
247 scheduled basis³². Where state law mandates equipment and facilities, such statutes should supersede this
248 guideline³².

249
250 **Occupational safety**
251 In the medical literature, long-term exposure to nitrous oxide used as a general anesthetic has been linked
252 to bone marrow suppression and reproductive system disturbances^{7,47-49}. However, it has been shown that
253 appropriate scavenging is effective in reducing these reproductive system effects^{19,50}. In an effort to
254 reduce occupational health hazards associated with nitrous oxide, the AAPD recommends exposure to
255 ambient nitrous oxide be minimized through the use of effective scavenging systems and periodic
256 evaluation and maintenance of the delivery and scavenging systems⁵¹⁻⁵³.

257
258 **References**
259 1. American Dental Association. Guideline for the use of sedation and general anesthesia by dentists.
260 200716. Available at "http://www.ada.org/sections/about/pdfs/anesthesia_guidelines.pdf".
261 [http://www.ada.org/en/~media/ADA/Education%20and%20Careers/Files/ADA_Sedation_Use_Gu](http://www.ada.org/en/~media/ADA/Education%20and%20Careers/Files/ADA_Sedation_Use_Guidelines)
262 [idelines](http://www.ada.org/en/~media/ADA/Education%20and%20Careers/Files/ADA_Sedation_Use_Guidelines)". Accessed March 13, 2013 August 20, 2017.

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

- 263 2. American Society of Anesthesiologists. Practice guidelines for sedation and analgesia by non-
264 anesthesiologists: An updated report by the American Society of Anesthesiologists task force on
265 sedation and analgesia by non-anesthesiologists. *Anesthesiology* 2002;96:1004-17.
- 266 3. Groenbaek A, Svensson P, Vaeth M, Hansen I, Poulsen S. A placebo-controlled, double-blind,
267 crossover trial on analgesic effect of nitrous oxide-oxygen inhalation. *Int J Paediatr Dent*
268 *2014;24:69-75.*
- 269 4. Paterson SA, Tahmassebi JF. Pediatric dentistry in the new millennium: Use of inhalation sedation
270 in pediatric dentistry. *Dent Update* 2003;30(7):350-6, 358.
- 271 5. Dock M, Creedon RL. Pharmacologic management of patient behavior. In: Dean JA, Avery DR,
272 McDonald RE, eds. McDonald and Avery's Dentistry for the Child and Adolescent. 9th ed.
273 Maryland Heights, Mo: Mosby; 2011:261-4.
- 274 6. Emmanouil DE, Quock RM. Advances in understanding the actions of nitrous oxide. *Anesth Prog*
275 2007;54(1):9-18.
- 276 7. Sanders RDB, Weimann J, Maze M. Biologic effects of nitrous oxide: A mechanistic and
277 toxicologic review. *Anesthesiology* 2008;109(4):707-22.
- 278 8. Foley J. A prospective study of the use of nitrous oxide inhalation sedation for dental treatment in
279 anxious children. *Eur J Paediatr Dent* 2005;6(3):21-7.
- 280 9. Holyroyd I. Conscious sedation in pediatric dentistry: short review of the current UK guidelines and
281 the technique of inhalational sedation with nitrous oxide. *Paediatr Anaesth* 2008;18(1):13-7.
- 282 10. Lyratzopoulos G, Blain KM. Inhalation sedation with nitrous oxide as an alternative to dental
283 general anesthesia for children. *J Public Health Med* 2003;25(4):303-12.
- 284 11. Wilson S, Gosnell E. Survey of American Academy of Pediatric Dentistry on nitrous oxide and
285 sedation: 20 years later. *Pediatr Dent* 2016;38(5): 385-392.
- 286 12. Haupt M, Limb R, Livingston R. Clinical effects of nitrous oxide conscious sedation in children.
287 *Pediatr Dent* 2004; 26 (1): 29-36.
- 288 13. Wilson S. Management of child patient behavior: quality of care, fear and anxiety, and the child
289 patient. *J Endod* 2013; 39(3s): S73-S77.
- 290 14. Yasny J, White J. Environmental implications of anesthetic gases. *Anesth Prog* 2012;59:154-158.
- 291 15. Levering NJ, Welie JVM. Current status of nitrous oxide as a behavior management practice
292 routine in pediatric dentistry. *J Dent Child* 2011;78(1):24-30.
- 293 16. McGain F. Why anesthetists no longer use nitrous oxide. *Anaesth Intensive Care* 2007;35(5):808-9.
- 294 17. Duncan GH, Moore P. Nitrous oxide and the dental patient: A review of adverse reactions. *J Am*
295 *Dent Assoc* 1984;108(2):213-9.

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

- 296 18. Clark MS, Brunick AL. Handbook of nitrous oxide and oxygen sedation.4th ed. St. Louis, Mo:
297 Mosby Elsevier; 2015:84-86;90-98.
- 298 19. Rowland AS, Baird DD, Shore DL, Weinberg CR, Savitz DA, Wilcox AJ. Nitrous oxide and
299 spontaneous abortion in female dental assistants. Am J Epidemiol 1995;141(6):531-7.
- 300 20. Fleming P, Walker PO, Priest JR. Bleomycin therapy: A contraindication to the use of nitrous
301 oxide-oxygen psychosedation in the dental office. Pediatr Dent 1988;10(4):345-6.
- 302 21. Selzer R, Rosenblatt D, Laxova R, Hogan K. Adverse effect of nitrous oxide in a child with 5,10-
303 methylene-tetrahydrofolate reductase deficiency. N Engl J Med 2003;349(1):45-50.
- 304 22. Ogundipe O, Pearson MW, Slater NG, Adepegba T, Westerdale N. Sickle cell disease and nitrous
305 oxide-induced neuropathy. Clin Lab Haematol 1999;21(6):409-12.
- 306 23. Fish BM, Banerjee AR, Jennings CR, et al. Effect of anaesthetic agents on tympanometry and
307 middle-ear effusions. J Laryngol Otol 2000;114(5):336-8.
- 308 24. Moss E, McDowall DG. ICP increase with 50% nitrous oxide in oxygen in severe head injuries
309 during controlled ventilation. Br J Anaest 1979;51(8):757-61.
- 310 25. American Academy of Pediatric Dentistry. Best practices on oral healthcare for the pregnant
311 adolescent. Pediatr Dent 2017; 39(6):221-228.
- 312 26. Klein U, Robinson TJ, Allshouse A. End-expired nitrous oxide concentrations compared to
313 flowmeter settings during operative dental treatment in children. Pediatr Dent 2011;33(1):56-62.
- 314 27. Klein U, Bucklin BA, Poulton TJ, Bozinov D. Nitrous oxide concentrations in the posterior
315 nasopharynx during administration by nasal mask. Pediatr Dent 2004;26(5):410-6.
- 316 28. Malamed SF. Sedation: A Guide to Patient Management. 5th ed. St. Louis, MO: Mosby Elsevier;
317 2010:248-59.
- 318 29. Malamed SF, Clark MS. Nitrous oxide-oxygen: A new look at a very old technique. J Calif Dent
319 Assoc 2003;31(5):397-403.
- 320 30. Guelmann M, Brackett R, Beavers N, Primosch RE, Effect of continuous versus interrupted
321 administration of nitrous oxide-oxygen inhalation on behavior of anxious pediatric dental patients:
322 a pilot study. J Clin Pediatr Dent 2012 Fall;37(1):77-82.
- 323 31. Clark MS. Contemporary issues surrounding nitrous oxide. In: Malamed SF, ed. Sedation: A Guide
324 to Patient Management. 5th ed. St. Louis, Mo: Mosby Elsevier; 2018:256.
- 325 32. American Academy of Pediatrics, American Academy of Pediatric Dentistry. Guidelines for
326 monitoring and management of pediatric patients before, during and after sedation for diagnostic
327 and therapeutic procedures: ~~An Update 2016.~~ Pediatr Dent 2016; 38(6):216-245.06;28(suppl):115-
328 32.

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

- 329 33. Donaldson D, Meechan JG. The hazards of chronic exposure to nitrous oxide: An update. *Br Dent J*
330 1995;178(3):95-100.
- 331 34. Kupietzky A, Tal E, Shapira J, Ram D. Fasting state and episodes of vomiting in children receiving
332 nitrous oxide for dental treatment. *Pediatr Dent* 2008;30(5):414-9.
- 333 35. Galeotti A, Garret ernardin A, D'Anto V, Ferrazzano GF, Gentile T, Viarani V, Cassabgi G, Cantile
334 T. Inhalation Conscious Sedation with Nitrous Oxide and Oxygen as Alternative to General
335 anesthesia in Precooperative, Fearful, and Disabled Pediatric Dental Patients: A Large Survey on
336 688 Working Sessions. *Biomed Res Int.* 2016;7289310. Epub Sep 26.
- 337 36. Hosey MT. UK National Clinical Guidelines in Paediatric Dentistry. Managing anxious children:
338 The use of conscious sedation in paediatric dentistry. *Int J Paediatr Dent* 2002;12(5):359-72.
- 339 37. Schmitt EL, Baum VC. Nitrous oxide in pediatric anesthesia: Friend or foe? *Curr Opin*
340 *Anaesthesiol* 2008;21(2):356-9.
- 341 38. Zeir JL, Doescher JS. Seizures temporarily associated with nitrous oxide administration for
342 pediatric procedural sedation. *J Child Neurol* 2010;25(12):1517-20.
- 343 39. Hogue D, Ternisky M, Iranour B. The response to nitrous oxide analgesia in children. *ASDC J Dent*
344 *Child* 1971;38(2):129-33.
- 345 40. Dunn-Russell T, Adair S, Sams DR, Russell CM, Barenie JT. Oxygen saturation and diffusion
346 hypoxia in children following nitrous oxide sedation. *Ped Dent* 1993;16(2):88-92.
- 347 41. Quarnstrom FC, Milgrom P, Bishop MJ, DeRouen TA. Clinical Study of Diffusion Hypoxia After
348 Nitrous Oxide Analgesia. *Anesth Prog* 1991;38:21-23.
- 349 42. Khinda V, Bhuria P, Khinda P, Kallar S, Brar G. Comparative evaluation of diffusion hypoxia and
350 psychomotor skills with or without postsedation oxygenation following administration of nitrous
351 oxide in children undergoing dental procedures: a clinical study. *J Indian Soc Pedod Prev Dent*
352 2016; 34(3): 217-222.
- 353 43. Donaldson M, Donaldson D, Quarnstrom F. Nitrous oxide-oxygen administration: when safety
354 features are no longer safe. *JADA* 2012;143(2):134-143.
- 355 44. American Dental Association. Oral Health Topics – Nitrous Oxide Dental Best Practices for
356 Nitrous Oxide-Oxygen Use 2017 Available at “[http://www.ada.org/en/member-center/oral-health-](http://www.ada.org/en/member-center/oral-health-topics/nitrous-oxide)
357 [topics/nitrous-oxide](http://www.ada.org/en/member-center/oral-health-topics/nitrous-oxide)”. Accessed August 2017.
- 358 45. Chrysikopoulou A, Matheson p, Miles M, Shey Z, Houpt M, Effectiveness of Two Nitrous Oxide
359 Scavenging Nasal Hoods During Routine Pediatric Dental Treatment. *Ped Dent* 2006, 28(3): 242-
360 247.

This draft does not constitute an official AAPD health oral policy or clinical recommendation until approval by the General Assembly. Circulation is limited to AAPD members.

- 361 46. Freilich MM, Alexander L, Sandor GKB, Judd P.. Effectiveness of 2 Scavenger Mask Systems for
362 Reducing Exposure to Nitrous Oxide in a Hospital-Based Pediatric Dental Clinic: A Pilot Study.
363 JCDA 2007;73(7):615-615d
- 364 47. Corcetti M, Serwint JR. Inhalants. *Pediatr Rev* 2008;29(1):33-4.
- 365 48. Lehmborg J, Waldner M, Baethmann, Eberhard UHL. Inflammatory response to nitrous oxide in
366 the central nervous system. *Brain Res* 2008;1246:88-95.
- 367 49. Luhmann JD, Kennedy RM. Nitrous oxide in the pediatric emergency department. *Clin Pediatr*
368 *Emerg Med* 2000;1(4):285-9.
- 369 50. Rowland AS, Baird DD, Shore DL, Weinberg CR, Shore DL, Shy CM, Wilcox AJ. Reduced
370 Fertility among Women Employed as Dental Assistants Exposed to High Levels of Nitrous Oxide.
371 N Engl J Med 1992;327:993-997.
- 372 51. American Academy of Pediatric Dentistry. Policy on minimizing occupational health hazards
373 associated with nitrous oxide. *Pediatr Dent* 2013;~~35(special issue):80-4~~ 38(6):92-93.
- 374 52. Rademaker AM, McGlothlin JD, Moenning JE, Bagnoli M, Carlson G, Griffin C. Evaluation of two
375 nitrous oxide scavenging systems using infrared thermography to visualize and control emissions. *J*
376 *Am Dent Assoc* 2009;140(2):190-9.
- 377 53. National Institute for Occupational Safety and Health (NIOSH). Control of nitrous oxide in dental
378 operatories 1996. Available at, <https://www.cdc.gov/niosh/docs/hazardcontrol/hc3.html>. Accessed
379 August 21, 2017.
- 380
- 381 ~~Kinouei K, Tanigami H, Tashiro C, Nishimura M, Fukumitsu K, Takauchi Y. Duration of apnea in-~~
382 ~~anesthetized infants and children required for desaturation of hemoglobin to 95%. *Anesthesiology*~~
383 ~~1992;77(6):1105-7.~~
- 384 ~~Nathan JE. Management of the difficult child: A survey of pediatric dentists' use of restraints, sedation,~~
385 ~~and general anesthesia. *J Dent Child* 1989;54(4):291-301.~~
- 386 ~~Patel R, Lenczyk M, Hannallah RS, McGill WA. Age and onset of desaturation in apnoeic children. *Can J*
387 ~~*Anaesth* 1994;41(9):771-4.~~~~
- 388 ~~Patel R, Norden J, Hannallah RS. Oxygen administration prevents hypoxemia during post anesthesia-~~
389 ~~transport in children. *Anesthesiology* 1988;69(4):616-8.~~
- 390 ~~Stach DJ. Nitrous oxide sedation: Understanding the benefit and risks. *Am J Dent* 1995;8(1):47-50.~~